

From: [REDACTED]
Sent: 23 April 2008 16:49
To: Natalie Bemrose
Subject: Health Technology Appraisals

Dear Natalie,
Southwark PCT's response to the following HTA is as follows;

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women

i) whether you consider that all of the relevant evidence has been taken into account

Response: Yes

ii) whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate

Response: Yes

iii) whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.

Response: Yes

Regards

[REDACTED]

[REDACTED]
Southwark Primary Care Trust
Dulwich Locality
2nd floor, Woodmill building
Neckinger
Se16 3QN

[REDACTED]

[REDACTED]

Delivered via MessageLabs
